Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

Hong, Yong Sang, Kim, Sun Young, Lee, Ji Sung, Nam, Byung-Ho, Kim, Kyu-pyo, Kim, Jeong Eun, Park, Young Suk, Park, Joon Oh, Baek, Ji Yeon, Kim, Tae-You, Lee, Keun-Wook, Ahn, Joong Bae, Lim, Seok-Byung, Yu, Chang Sik, Kim, Jin Cheon, Yun, Seong Hyeon, Kim, Jong Hoon, Park, Jin-hong, Park, Hee Chul, Jung, Kyung Hae, Kim, Tae Won · 2019 · Journal of Clinical Oncology

Abstract

PURPOSE: We evaluated the role of oxaliplatin as adjuvant chemotherapy in patients with rectal cancer who received preoperative chemoradiotherapy (CRT) with fluoropyrimidine monotherapy and total mesorectal excision (TME). METHODS: The ADORE trial (adjuvant oxaliplatin in rectal cancer) is a multicenter, randomized trial in patients with postoperative ypStage II (ypT3-4N0) or III (ypT any N1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and TME. Patients were randomly assigned (1:1) to receive adjuvant chemotherapy either with FL (fluorouracil 380 mg/m 2 and leucovorin 20 mg/m 2) or FOLFOX (oxaliplatin 85 mg/m 2, leucovorin 200 mg/m 2, and fluorouracil bolus 400 mg/m 2 on day 1, fluorouracil infusion 2,400 mg/m 2 for 46 hours). Stratification factors included ypStage and participating center. Primary end point was disease-free survival (DFS). RESULTS: A total of 321 patients were enrolled between November 19, 2008, and June 12, 2012. Six-year DFS rates were 68.2% in the FOLFOX arm versus 56.8% in the FL arm, with a stratified hazard ratio of 0.63 (95% CI, 0.43 to 0.93; P = .018) by intention-to-treat analysis. In the subgroup analysis for DFS, FOLFOX was favorable versus FL in patients with ypStage III, ypN1b, ypN2, high-grade histology, minimally regressed tumor, and an absence of lymphovascular or perineural invasion. Six-year overall survival rate was 78.1% in the FOLFOX arm versus76.4% in the FL arm (hazard ratio, 0.73; 95% CI, 0.45 to 1.19; P = .21). In the subgroup analysis for OS, FOLFOX was favorable versus FL in patients with ypN2 and minimally regressed tumor. CONCLUSION: Adjuvant FOLFOX improved DFS in patients with rectal cancer with ypStage II and III disease after preoperative CRT. Adjuvant FOLFOX may be considered on the basis of the postoperative pathologic stage in those who received preoperative CRT and TME.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.00016

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 163

Metadata

Authors
Hong, Y. S., Kim, S. Y., Lee, J. S., Nam, B.-H., Kim, K.-P., Kim, J. E., Park, Y. S., Park, J. O., Baek, J. Y., Kim, T.-Y., Lee, K.-W., Ahn, J. B., Lim, S.-B., Yu, C. S., Kim, J. C., Yun, S. H., Kim, J. H., Park, J.-H., Park, H. C., Jung, K. H., & Kim, T. W.
Venue
Journal of Clinical Oncology
Published
2019-11-20
Volume
37
Issue
33
Pages
3111-3123
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2979779879
Cited by
163
References
5
FWCI
7.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. https://app.cochat.ai/papers/10.1200/jco.19.00016
The paper
Hong, Y. S., Kim, S. Y., Lee, J. S., Nam, B.-H., Kim, K.-P., Kim, J. E., Park, Y. S., Park, J. O., Baek, J. Y., Kim, T.-Y., Lee, K.-W., Ahn, J. B., Lim, S.-B., Yu, C. S., Kim, J. C., Yun, S. H., Kim, J. H., Park, J.-H., Park, H. C., . . . Kim, T. W. (2019). Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.00016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.